Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 37

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
407 shares outstanding at March 31, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 202447 47 Treasury stock, at cost, 837,240 shares at March 31, 2025 and December 31, 2024, inclusive of excise tax(25,121)(25,121)     Additional paid-in capital1,023,808 1,009,435      Accumulated deficit(201,544)(206,356)     Accumulated other comprehensive income1,351 343           Total stockholders’ equity798,541 778,348           Total liabilities and stockholders’ equity$1,586,669 $1,553,516  

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 4

Table of Contents

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months EndedMarch 31, 20252024Revenues:  Net product sales$167,594 $165,824 Royalty revenue1,329 1,293           Total revenues168,923 167,117 Operating expenses:  Cost of goods sold34,306 47,416 Research and development25,342 18,238 Selling, general and administrative86,776 72,026 Amortization of acquired intangible assets14,322 14,322 Contingent consideration gains, acquisition-related expenses, restructuring and other6,187 1,903           Total operating expenses166,933 153,905 Income from operations1,990 13,212 Other income (expense):  Interest income6,895 3,903 Interest expense(4,580)(3,316)Other, net4,401 (159)          Total other income, net6,716 428 Income before income taxes8,706 13,640 Income tax expense(3,894)(4,661)Net income$4,812 $8,979 Net income per common share:  Basic and diluted net income per common share$0.10 $0.19